Recent research have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GCGR agonists are commonly employed for addressing type 2 diabetes, https://cecilytajd272701.articlesblogger.com/63999590/emerging-gcgr-stimulators-and-dopamine-modulation-a-comparative-overview